Epilepsy in a mouse model of GNB1 encephalopathy arises from altered potassium (GIRK) channel signaling and is alleviated by a GIRK inhibitor
mutations in , encoding the G subunit of G proteins, cause a neurodevelopmental disorder with global developmental delay and epilepsy, encephalopathy. Here, we show that mice carrying a pathogenic mutation, K78R, recapitulate aspects of the disorder, including developmental delay and generalized sei...
Saved in:
Published in | Frontiers in cellular neuroscience Vol. 17; p. 1175895 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Research Foundation
18.05.2023
Frontiers Media S.A |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | mutations in
, encoding the G
subunit of G proteins, cause a neurodevelopmental disorder with global developmental delay and epilepsy,
encephalopathy. Here, we show that mice carrying a pathogenic mutation, K78R, recapitulate aspects of the disorder, including developmental delay and generalized seizures. Cultured mutant cortical neurons also display aberrant bursting activity on multi-electrode arrays. Strikingly, the antiepileptic drug ethosuximide (ETX) restores normal neuronal network behavior
and suppresses spike-and-wave discharges (SWD)
. ETX is a known blocker of T-type voltage-gated Ca
channels and G protein-coupled potassium (GIRK) channels. Accordingly, we present evidence that K78R results in a gain-of-function (GoF) effect by increasing the activation of GIRK channels in cultured neurons and a heterologous model (
oocytes)-an effect we show can be potently inhibited by ETX. This work implicates a GoF mechanism for GIRK channels in epilepsy, identifies a new mechanism of action for ETX in preventing seizures, and establishes this mouse model as a pre-clinical tool for translational research with predicative value for
encephalopathy. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Present addresses: Sophie Colombo, Dynacure, Illkirch-Graffenstaden, France Edited by: Haohua Qian, National Eye Institute (NIH), United States Reviewed by: Fouad Lemtiri-Chlieh, University of Connecticut, United States; Stefano Taverna, San Raffaele Hospital (IRCCS), Italy Sahar Gelfman, Regeneron Genetics Center, Tarrytown, New York, NY, United States David B. Goldstein, Actio Biosciences, San Diego, CA, United States |
ISSN: | 1662-5102 1662-5102 |
DOI: | 10.3389/fncel.2023.1175895 |